Nystrom & Associates Launches TMS for Treatment-Resistant Depression

Nystrom & Associates, a prominent behavioral health care provider, has commenced offering transcranial magnetic stimulation (TMS) using the advanced NeuroStar® therapy device. This service was launched with a ribbon-cutting event, signifying a significant milestone in the treatment of Major Depressive Disorder (MDD), particularly for patients who have not responded to traditional medication.

The clinics now providing TMS are located in Eden Prairie, Minnesota, and Iowa City, Iowa. During the launch, colleagues and stakeholders gathered to celebrate the addition of TMS therapy to Nystrom & Associates' Eden Prairie clinic. TMS therapy has demonstrated efficacy in alleviating depressive symptoms in 60-80% of patients. Although TMS was approved for general use over ten years ago, recent studies suggest that it may be more effective than previously thought. Its applications now potentially include conditions ranging from minor anxiety to Alzheimer's disease.

Mike Chappuis, Vice President of Medical Services at Nystrom & Associates, expressed enthusiasm about the new service. "When people are depressed, it's hard to function. We're excited to offer TMS because it broadens patient access to this transformative treatment and it offers hope and remission for those who need it most," he stated.

TMS therapy offers several advantages:
1. Minimal Side Effects: Clinical trials have shown that side effects are generally mild, with the most common being temporary discomfort at or near the treatment site.
2. Long-Lasting Results: Approximately 60-80% of patients experience improvement in depressive symptoms, with about two-thirds maintaining this benefit for a year.
3. Safe and Non-Invasive: TMS is FDA-cleared and can be used alongside other treatments without the need for anesthesia or sedation, allowing patients to return to normal activities immediately after each session.
4. Insurance Coverage: Most major insurance plans cover TMS therapy.

Jonathan Uecker, MD, Medical Director at Nystrom & Associates, highlighted the significance of this new treatment option. "Millions of people being treated for depression do not benefit from conventional medications. The addition of this breakthrough treatment provides adult sufferers access to a proven, non-pharmaceutical approach to improving Major Depressive Disorder," he said.

Nystrom & Associates is a multidisciplinary group of professionals offering services in psychiatry, psychology, clinical social work, marriage and family therapy, substance use disorder treatment, and nursing. With approximately 2,000 employees across more than 60 locations in Minnesota, Iowa, Wisconsin, Missouri, and North Dakota, Nystrom & Associates provides comprehensive care to individuals and families dealing with personal, emotional, marital, or psychological challenges. Furthermore, the organization extends its services through tele-behavioral health and addiction treatment programs.

TMS therapy represents a significant advancement in the treatment of depression, offering a new ray of hope for patients who have found little relief from conventional medications. As Nystrom & Associates continues to expand its services, the introduction of TMS marks a noteworthy commitment to improving mental health outcomes for its patients.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!